- Our Team
- Neurological Bulletin
The University of Massachusetts Medical School's Neurology department is the largest training, research and clinical neurology facility in central New England. Our Neurology Residency Program is clinically and intellectually at the very center of our department and the training of new neurologists is among our most important and most enjoyable responsibilities. Designed to encompass both the richness of traditional clinical neurology and the excitement of contemporary clinical neuroscience, our goal is to train superb clinical neurologists who are experienced in the principles of neurological disease and are also well-educated clinical neuroscientists informed about the structure, function and molecular physiology of the nervous system.
This is an exciting time in neurology as powerful new technologies in basic neurobiology and the clinical neurosciences have rapidly improved our understanding of neurological illnesses. Prospects have never been better for finding effective new treatments for even the most devastating neurological disorders. While our program centers on a first-rate core clinical experience, our residents and faculty are encouraged to continually advance their training through customized residency programs, specialized fellowships and research opportunities. The laboratories of our skilled faculty explore the exciting and growing fields of neurology as new technologies accelerate our understanding of the central nervous system and the diseases that plague it.
A high level of research is supported by multiple funding resources which drive a variety of programs including helping to unravel the genetic defects that cause familial forms of Lou Gehrig’s disease (amyotrophic lateral sclerosis, or ALS), molecular events that trigger non-familial forms of ALS, and drug screening for small molecules that ameliorate this disease. Studies into the genetic basis and approaches to therapy of selected other neuromuscular disorders include a form of limb girdle muscular dystrophy (LGMD-2B, also known as Miyoshi myopathy), periodic paralysis, hereditary sensory and autonomic neuropathy (HSAN1) and a form of adrenoleukodystrophy (Lorenzo’s Oil disease) known as adrenomyeloneuropathy. Ongoing investigations continue into the physiology of the visual cortex and the pathology, genetics and biology of other neurodegenerative disorders such as Alzheimer’s disease. Studies of the molecular control of circadian regulation and the genetics of membrane channel function and dysfunction aid in the understanding of channelopathies. Research within the Neurology Department also includes making insights into the pathophysiology of disorders in the central and peripheral autonomic nervous systems, therapeutic approaches to multiple sclerosis, and pathobiology of brain tumors.
Our combined emphasis on research and our training excellence help define the Neurology Department at the University of Massachusetts Medical School as a leader in innovation and treatment throughout New England.
Alumna Diane M. Riccio, PhD '03 and her husband have pledged $1 million to the UMass ALS Fund, the largest alumni donation ever to UMass Medical School.
The Governor Cellucci Tribute Road Race to raise funds for ALS research. This 5k run in the town of Hudson, MA will be on August 2nd, 2014 and is open to both runers and walkers. Additional details.
Dr. Marc Fisher has been named Editor-in-Chief of the journal Stroke
Medical Center Receives Highest Designation For Stroke Care From American Heart Association, the Stroke Service Gold Plus Quality Achievement award
Research in Neurology
Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis
Researcher Chi-Hong Wu in the laboratory of Dr. John Landers identifies actin filament building gene, PFN1, as a cause of ALS.
Nature. 2012 Aug 23;488(7412):499-503
The Department of Neurology at the University of Massachusetts Medical School (UMMS) is recruiting a clinician-scientist with expertise in neurodegeneration with an emphasis in movement disorders and dementia. This individual will hold an endowed chair and have a unique opportunity to assume a leadership position in innovative research into the molecular biology and therapeutic strategies for these disorders.